Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2003-06-19
2008-11-25
Wilson, James O. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C564S161000
Reexamination Certificate
active
07456219
ABSTRACT:
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: RE38506 (2004-04-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammet et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0018968 (2004-01-01), Sgouros et al.
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2004/0266818 (2004-12-01), Breslow et al.
patent: 2005/0004007 (2005-01-01), Grant et al.
patent: 2006/0167103 (2006-07-01), Bacopoulos et al.
patent: 2006/0276547 (2006-12-01), Bacopoulos et al.
patent: 2007/0060614 (2007-03-01), Bacopoulos et al.
patent: 0547000 (1993-06-01), None
patent: WO 95/31977 (1995-11-01), None
patent: WO 98/39965 (1998-09-01), None
patent: WO 98/40080 (1998-09-01), None
patent: WO 98/55449 (1998-10-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/15921 (2002-02-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/055017 (2002-07-01), None
patent: WO 02/085400 (2002-10-01), None
Stowell et al. Journal of Medicinal Chemistry, 1995, 38, 1411-1413.
Adams and Elliott (2000). Oncogene 19: 6687-6692.
Bates et al. (1999). Proc. American Society of Clinical Oncology 18: 180a, Abstract No. 693.
Cao et al.(2001).Am. J. Respir. Cell Mol. Biol., 25:562-8.
Foster et al. (1997). Invest. New Drugs 15: 187-194.
Gojo et al. (2002). Blood 100: Abstract No. 2198.
Gore and Carducci (2000). Exp. Opin. Invest. Drugs 9: 2923-2934.
Huang and Pardee (2000). Molecular Medicine 6: 849-866.
Johnstone, R. (2002). Nature Reviews Drug Discovery 1: 287-299.
Kelly et al. (2002). Exp. Opin. Invest. Drugs 11: 1695-1713.
Kelly, et al. (2003).Clinical Cancer Research 9:3578-3588.
Kosugi et al. (2001). Jpn. J. Cancer Res. 92: 529-536.
Marshall et al. (2002). J. Exp. Therapeutics and Oncology 2: 325-332.
O'Connor et al. (2001).Journal of the American Society of Hematology611a, Abstract No. 2562.
Piekarz et al. (2001). Blood 98: 2865-2868.
Prakash et al. (2001). Invest. New Drugs 19: 1-11.
Rha et al. (1993). J. Korean Med. Sci. 8:251-256.
Rifkind et al. (2002). 224th ACS National Meeting, Boston, MA Abstract No. 226.
Sandor et al. (2002). Clinical Cancer Research 8: 718-728.
Secrist et al. (2003). Curr. Opin. Invest. Drugs 4:1422-1427.
Summerhayes, M. (2001). J. Oncol. Pharm. Prac. 7: 107-125.
Vigushin, D. (2002). Current Opin. Invest. Drugs 3: 1396-1402.
Waheed et al. (2000).Proceedings of the American Association for Cancer Research, 41:808.
Warrell et al. (1998). J. Natl. Cancer Institute 90: 1621-1625.
Weiser et al. (2001).J. Immunother., 24:151-61.
Wu et al. (2001). “Negative Regulation of bcl-2 Expression by p53 in Hematopoietic Cells.”Oncogene 20(2): 240-251, Abstract, Database CAPLUS on STN, Acc. No. DN134:293668.
“Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA”, Oct. 30, 2002.
“Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias”, Jul. 1, 2003.
“Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development”, Sep. 20, 2002.
“Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO”, Jun. 2, 2003.
“Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium”, Nov. 21, 2002.
“Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial”, Oct. 13, 2003.
“Aton Pharma, Inc. Reports on Phase I Trial of SAHA”, Aug. 14, 2002.
Adhikari, D et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1998), vol. 39, p. 312, “Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate”.
Alexandrov, I et al., FEBS Letters, (1998), vol. 434, pp. 209-214, “Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations”.
Almenara, J et al., Leukemia (2002), vol. 16, pp. 1331-1343, “Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)”.
Amin HM et al., British Journal of Haematology (2001), vol. 115, pp. 287-297, “Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyelocytic Leukaemia with t(15;17)”.
Aron, JL et al., Blood (2003), vol. 102, No. 2, pp. 652-658, “Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent With Activation of Caspase 8-mediated Apoptosis and Down-Regulation of c-FLIP Protein”.
Benoit, NE et al., Immunopharmacology, (1996), vol. 35, pp. 129-139, “Increased inhibition of Proliferation of Human B Cell Lymphomas Following Litigation of CD40, and Either CD19, CD20, CD95 or Surface Immunoglobulin”.
Bode, J et al., Journal of Interferon Research, (1982), vol. 2, No. 2, pp. 159-166, “Links Between Effectsof Butyrate on Histone Hyperacetylation and Regulation of interferon Synthesis in Namalva and FS-4 Cell Lines”.
Buckley, AR et al., Cell Growth & Differentiation (1996), vol. 7, pp. 1713-1721, “Alterations in pim-1 and c-myc Expression Associated with Sodium Butyrate-induced Growth Factor Dependency in Autonomous Rat Nb2 Lymphoma Cells”.
Buckley, AR et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1997), vol. 38, p. 193, “Reversal of Apoptosis Resistance by Butyrate in rat Nb2 Lymphoma Cells”.
B
Chiao Judy H.
Miller Thomas A.
Richon Victoria M.
Elrifi, Esq. Ivor R.
Merck HDAC Research, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo PC
Valenrod Yevgeny
Wilson James O.
LandOfFree
Polymorphs of suberoylanilide hydroxamic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphs of suberoylanilide hydroxamic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of suberoylanilide hydroxamic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045324